TNFRSF9 and neoplasm: One such strategy is the use of bsAb, which minimizes off-target tumor toxicity by designing the antibody to preferentially bind specifically to tumor cells and be enriched in the tumor microenvironment, and then to bind to 4-1BB and achieve activation of 4-1BB signaling.